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“...treat future trials as an opportunity to apply our best science 
not only to product development but to the community 
dimensions of clinical trial planning and implementation”- 
Newman, PA. 2006
  
  
ABSTRACT 
Background: As HIV infection continues to be a public health problem, development 
of an effective preventive HIV vaccine is a priority. For the ultimate development of an 
AIDS vaccine, clinical trials are being conducted throughout the world. However, the 
process of developing the vaccine does not only depend on identification of suitable 
trial candidates, but also requires knowledge of incentives to participate in the 
community where the trial is being conducted. Therefore, the studies presented in this 
thesis are components of a HIV/AIDS and HIV vaccine trial project in Dar es Salaam, 
Tanzania to address motivations and deterrents of participating in an HIV vaccine trial. 
  
Aim: To examine the motivations and deterrents for participating in preventive HIV 
vaccine trials.  
 
Methods: Data were collected from participants and volunteers who were considered 
for participation or participated in a phase I/II HIV vaccine trial. Four studies with 
different designs were conducted. In Study I, a semi-structured interview administered 
questionnaire was used to assess willingness to volunteer for a phase I/II HIV vaccine 
trial. A convenience sample of 329 individuals from the police force cohort was 
recruited for the study in 2005-2006. In Study II, focus group discussions were 
conducted to explore factors that would influence participation in an HIV vaccine trial 
among members of the police force in 2006-2007. In Study III, face-to-face interviews 
were used to identify reasons for declining to enrol in an HIV vaccine trial among those 
who agreed to enrol at the start and were randomized for the trial in 2007-2009. In 
Study IV, we used focus group discussions to evaluate the experiences of those who 
participated in the phase I/II trial in 2009. 
 
Results: Willingness to volunteer for an HIV vaccine trial was associated with 
intention to tell others, positive outcome of the trial, personal decision and expectation 
of obtaining protection against HIV infection. Participation in an HIV vaccine trial 
would be negatively influenced by sexual partners, friends, family members, relatives 
or parents (significant others) and fear of vaccine side-effects. Personal fears and 
negative influences from significant others were the main reasons for declining to enrol 
in an HIV vaccine trial. Despite the negative comments from significant others, 
volunteers in the HIV vaccine trial managed to stay on until the end of the trial as a 
result of personal decision and trial-related interventions.  
 
Conclusion: Personal decision is both a motivation to participate in an HIV vaccine 
trial and a reason to stay on until the end of trial. On the contrary, significant others are 
the deterrents to participation in the HIV vaccine trial and the reason for declining to 
enrol in the HIV vaccine trial. Awareness of these issues before trial implementation 
may help to maximize resource use and enhance retention of those who volunteer in the 
HIV vaccine trials.  
 
Keywords: Willingness, phase I/II, HIV, vaccine trial, motivation, enrolment, 
participation, police officers, Tanzania 
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PREFACE 
The choice of HIV vaccine trial as my PhD topic has a history, beginning when I met 
Associate Professor Muhammad Bakari in 2005. Muhammad Bakari was at that time 
the co-principal investigator in a large-scale HIV and AIDS project, the forerunner of 
the subsequent HIV vaccine trial in the cohort of police officers in Dar es Salaam. He 
invited me to join the project as a social scientist, and because my research interests 
were in HIV and AIDS, I accepted his invitation. That was my first stepping-stone to 
research in the social and behavioural aspects of the HIV vaccine trial project in the 
cohort of police officers in Dar es Salaam, Tanzania (2007-2011).  
 
Back in 1997, when I was doing a nursing internship at Muhimbili National Hospital 
(MNH), I saw an emaciated female patient sleeping in a remote corner, far away from 
the main entrance to the ward. With compassion, I felt like asking her about her 
condition, but she was quite obviously suffering from AIDS. A nurse pulled me aside: 
„Don‟t spend time in that place; it is infectious! [The nurse whispered]! I still remember 
the image of that patient who could be a „mama‟ [mother] of somebody / sister / friend / 
colleague, etc.‟ and the whisperings of the nurse. With the little knowledge I had about 
HIV and AIDS, I was confused about what to do. However, my confusion was allayed 
by a colleague with whom I shared the situation. He put me in contact with an 
organization that ran counselling courses, particularly for HIV/AIDS, that were funded 
by the British Council in Dar es Salaam. I felt proud after acquiring the skills I was 
lacking when I came across the sick woman and the nurse [poorly skilled in counselling 
techniques].  
 
After my internship (1998), I decided to apply my counselling and nursing skills to 
AIDS patients. I started working for Pastoral Activities and Services for people with 
AIDS in Dar es Salaam Archdiocese (PASADA) as a counsellor, community health 
nurse and later on as the director of home-based care services for people with AIDS up 
to 2002. PASADA is a non-governmental organization which has gained tremendous 
recognition because of its extensive non-discriminatory services to people with AIDS 
in Dar es Salaam and neighbouring regions. During my practice, I noted people visiting 
from a neighbouring region, Morogoro, partly to avoid stigma in their local district, but 
also to obtain quality services. My four years of working with PASADA were 
characterized by overwhelming challenges, especially the countless days of grieving for 
our clients. Premature deaths were very common because most clients showed up at a 
very late stage of their illness. We provided expertise in palliative care, but our 
services, including the provision of oral morphine to alleviate severe pain, were limited. 
Thanks God, today we have antiretroviral therapy (ART). Although not everyone who 
is eligible can get the treatment on time, I am sure that the availability of antiretroviral 
drugs (ARVs) has changed and prolonged the lives of many individuals.  
 
During my work experience, I noted another category of AIDS victim - the informal 
caregivers whose workload was doubled and who found themselves providing basic 
medical/nursing care to relatives with AIDS without having the proper skills; a 
situation that could predispose them to HIV infection and/or inappropriate management 
of AIDS patients. The details of caregivers and their contribution to AIDS care are 
available in my Master‟s thesis entitled: „Assessing the impact of HIV/AIDS on 
informal care: a qualitative study from an urban Tanzanian context‟. These findings are 
also published in Transcultural Nursing Journal, Vol. 1 .2009. The above exposure was 
a crucial factor in me staying in the field of HIV/AIDS research. Also, I believe that the 
  
contribution of social science to the development of an HIV vaccine is important 
especially in our cultural context.  Although no one is sure how long the vaccine 
journey will take, I am confident that People have Dreams, dreams that will eventually 
contribute to the development of an AIDS vaccine. 
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1 INTRODUCTION 
1.1 BACKGROUND   
For more than three decades, Human Immunodeficiency Virus (HIV) and its related 
disease, Acquired Immunodeficiency Syndrome (AIDS) have persisted without an 
effective preventive vaccine. Efforts are ongoing throughout the world to search for 
such a vaccine [1], but progress is hampered by both scientific [2-3] and social 
challenges in the recruitment of volunteers [4-8]. Scientists have discovered different 
forms of an HIV virus that have evolved over time. These forms are members of the 
same family tree with different branches known as clades (subtypes) [9], which exist in 
different parts of the world. The existence and distribution of different subtypes in the 
world [10-11] is a dilemma for scientists. Can a vaccine tested in one part of the world 
be used in other parts of the world? Clearly, multiple trials are needed for different 
subtypes in different parts of the world. Along with these trials, studies of the 
incentives and deterrents for participating in an HIV vaccine trial are key to 
understanding the acceptability of the trial in the community where it is being 
conducted.  
 
In previous studies, there has been increasing demand for basic HIV vaccine education 
to address certain vaccine trial concepts [12-21] in order to understand the conduct of 
HIV vaccine trials. Moreover, willingness to participate in HIV vaccine trials and the 
associated motivations and barriers have been broadly documented. In high-income 
countries, the motivations to participate in HIV vaccine trials include: a high perceived 
HIV threat [17], perceived protection [5, 22], higher self-related likelihood of HIV 
infection [21, 23], perceived high-risk behaviour [24], monetary incentives [25-26], and 
feeling comfortable about participation in an HIV vaccine trial [21, 27]. The barriers 
towards participation in HIV vaccine trials have also been identified in these countries: 
mistrust of government or scientists conducting the trials and fear of being stigmatized 
[5, 22, 25, 28], low perceived risk for HIV infection [5, 22], fear of vaccine induced 
HIV sero-positive [5, 22, 25, 28-29], side-effects of the vaccine [22, 25], longer trial 
duration [29] and effect of participation in the trial on relationships [22].  
 
In low-income countries, willingness to volunteer for HIV vaccine trials is positively 
associated with: a wish to prevent or stop the spread of HIV [16, 20, 30-31], perceived 
vaccine protection against AIDS and perceived family support for participation [32], 
helping researchers to find an effective vaccine [20], self-perception of HIV risk [12] 
and desire to have protective vaccine [15-16, 20, 33-34], assurances regarding stigma 
and confidentiality, and compensation for family in the event of poor vaccine outcome 
[16]. In Uganda, the high interest in a vaccine trial among participants was found to be 
influenced by unrealistic expectations such as being protected from HIV transmission 
while having multiple sexual partners or not using condoms [35]. However, a study 
among commercial sex workers in Kenya showed that fewer respondents would 
increase risk behaviour as a result of participation in an HIV vaccine trial [36]. The 
barriers identified in relation to participation in HIV vaccine trials in low-income 
countries are: possibilities of side-effects from the vaccine [15, 30], perceived risk of 
stigma [14, 32-33], fear of becoming HIV infected from the vaccine [15-16, 33], fear of 
discovering own HIV status [14],  physical risk [14, 34], effect of the vaccine on 
participants‟ lives and unknown efficacy of the trial [20], requirement to delay 
pregnancy and low-risk behaviour [34]. In addition, a growing body of literature shows 
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that altruism provides universally consistent motivation for HIV vaccine trial 
participation [5, 13, 16, 18, 34, 37-39]. 
 
Despite the fact that many trials have been conducted, few studies have explored the 
experiences of the volunteers who enrol in HIV vaccine trials. Those who enrol and 
stay on until the end of the trial have been noted to reduce their high-risk sexual 
behaviour [40-41]. However, some of the volunteers have encountered negative 
reactions from friends and family [42-45]  because of participating in the HIV vaccine 
trial. In addition, some studies have documented reasons for declining to enrol in HIV 
vaccine trials among eligible volunteers. The reasons include: trial duration [46-48], 
negative reactions from partner, family or friends [47], and concerns about false 
positive HIV test results and side-effects from the vaccine [47-48]. These studies 
provide unique knowledge on the uptake of HIV vaccine trials in different contexts, 
which may be useful even in the acceptability and uptake of a partially effective 
vaccine if made available.  
 
1.2 GLOBAL OVERVIEW OF HIV VACCINE TRIALS 
Increasingly, most HIV vaccine trials are performed in the United States and Europe 
with very few conducted in Africa [1, 11, 49]. Given the genetic variability [10], 
conducting HIV vaccine trials is important, both in high- and low-income countries. It 
is also logical to test the typical vaccine in various regions where they are likely to be 
used [9]. The first phase I trial was conducted in the US in 1987 [10] among 72 healthy 
adult volunteers and the first volunteer was immunized in February 1988 [50]. At the 
end of 2009, almost 200 trials, using a variety of vaccine types alone or in combination, 
were recorded in the International AIDS Vaccine Initiative (IAVI) Clinical Trials 
Database [3]. The first phase I/II vaccine trial in a developing country was conducted in 
China in 1993 [11].  Since then, more than 30 phases I and II trials have been 
completed in developing countries with several trials in Thailand, Brazil, Haiti, 
Botswana and South Africa, Zambia, Rwanda, Kenya and Uganda [1]. In 1999, Uganda 
was the first country in Africa to conduct a phase I/II HIV vaccine trial [1, 51-52]. The 
study evaluated safety and immunogenicity among healthy, HIV-negative, low-risk, 
adult male and female volunteers. None of the trial volunteers experienced significant 
local or systemic toxicity from the candidate vaccines tested in Uganda [51, 53-54]. 
HIV vaccine trials have also been performed in Kenya since 2001 [55-57]. In addition, 
a multi-site phase I/II HIV vaccine trial was conducted in the general population in 
Uganda, Kenya and Tanzania in 2003 [1, 58].  
 
Phase III HIV vaccine trials have also been conducted to assess the protective efficacy 
of different versions of candidate vaccine. So far, four AIDS efficacy trials have been 
completed: 1) The VAX004 trial using AIDSVAX B was conducted during 1998 in the 
US, Canada and the Netherlands among 5 403 men who have sex with men (MSM) and 
among women at high risk for heterosexual transmission of HIV-1 [9, 59-60]; 2) The 
VAX003 trial using AIDSVAX B/E, Clades B & E was conducted in Bangkok, 
Thailand between March 1999 and August 2000 among 2546 injection drug users [61]. 
Both trials did not indicate overall protective effect of the vaccine against acquisition of 
HIV infection. 3) The STEP trial using Adenovirus type 5 (Ad5) vaccine was 
conducted in the Americas, Caribbean and Australia among MSM and at-risk women 
[62-63]. Unfortunately, the trial was discontinued in 2007 because there was an 
increase of HIV-1 acquisition in subgroups of male vaccine recipients who had pre-
existing Ad5 antibody titres, and also were uncircumcised [62, 64]. Following the non-
efficacy results from the STEP trial, the Phambili trial in South Africa, which was using 
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the similar Ad5 vaccine, was also stopped before completion [64]. 4) Recently, a sign 
of hope for an effective vaccine came through the RV144 trial using ALVAC-HIV plus 
AIDSVAX B/E, Clades B&E which was conducted among the general population in 
Thailand. The trial results showed that the vaccine had the potential to lower the rate of 
HIV infection by 31% [65-66].  
 
(See Appendix I for stages of clinical trials and safety issues) 
 
1.3 THE NEED FOR AN HIV VACCINE FOR AFRICA 
An HIV vaccine is urgently needed for Sub-Saharan Africa because the majority of 
new HIV infections in the world continue to occur in selected countries in this region 
[67]. Similarly, it is important to conduct HIV vaccine trials in Tanzania because of a 
large number of new HIV infections [68].  
 
Risky sexual behaviour in Tanzania 
In Tanzania, the HIV epidemic is fuelled by an increase in the high-risk behaviour of 
having unprotected heterosexual intercourse with multiple sexual partners [68]. In 
recent years, the national response has been directed towards increasing individual and 
community awareness of the risk of HIV and its implications for the individual, the 
family and the community [69]. Even with preventive efforts such as large-scale 
information campaign and widespread condom distribution [70], new infections 
continue to occur due to people having unprotected sex with concurrent sexual partners 
[70-74]. In 2008, it was found that less that 50% of people aged 15-49 years old used a 
condom during their most recent higher risk intercourse (sexual intercourse with a non-
marital or non-cohabiting partner) [68]. For both men and women, urban residents have 
higher levels of HIV infection than rural residents (9 and 5 percent respectively). In a 
previous study among police officers, the HIV prevalence was comparable to that of 
the general population, and condom use was low [75]. Therefore, unprotected 
heterosexual intercourse which accounts for over 90% of new HIV infections remains 
the primary mechanism for HIV transmission in Tanzania [68]. Thus, more HIV 
transmissions are likely to continue in some populations in Tanzania.  
 
Although antiretroviral therapy (ART) is available in Tanzania, only 32% of people 
living with HIV are able to access it [67]. ART is given to people who are already 
infected with HIV to prolong their lives, but efforts towards development of an 
effective preventive vaccine for those who are HIV-negative are a priority. However, 
with persistent risky sexual practices and even the stigma surrounding ART use, 
participation in preventive HIV vaccine trials may bring a new challenge, namely that 
participants will be guided to practice safe sex which may not be a shared norm for 
many people.  
 
Sexual behaviour, use of ART and stigma 
Little research has been performed on sexual behaviour in relation to ART use or 
adherence to ART in Africa. In Uganda, Bunnel et al found that provision of ART, 
prevention counselling (including partner voluntary counselling) and testing decreased 
high-risk sexual behaviour and sexually transmitted HIV infection [76]. In a previous 
review, introduction to ART showed both an increase and decrease in high-risk sexual 
behaviour among clients [77]. In addition,  a multivariate analysis of the relationship 
between ART, adherence and unprotected sex suggests that a decrease in high-risk 
sexual behaviour depends on adherence among enrolled patients [78].  However, in 
some parts of Africa, availability of ART was found to bring a new source of stigma; 
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those on ART were perceived as a threat to the well-being of the HIV-negative 
members of the community [79-82]. It is important to understand issues surrounding 
sexual behaviour, stigma towards HIV/AIDS and ART use in the African context. This 
information may guide the researchers in predicting what may happen when 
implementing preventive HIV vaccine trials as well as in the event of a partially 
effective preventive vaccine being available. 
 
1.4 AN OVERVIEW OF HIV VACCINE TRIALS IN TANZANIA 
Tanzania is among the very few countries in Africa conducting HIV vaccine trials. 
Consequently, a cohort of police officers in Dar es Salaam was recruited to assess its 
suitability for future HIV vaccine trials in 1994. Between 1994-1998, the prevalence 
and crude HIV-1 incidence among members of the police force was determined and 
was found to be 13.8% and 19.6/1000 PYAR respectively [75]. According to WHO 
recommendations [83], these results showed that the police officer cohort would be a 
potential suitable population for HIV vaccine trials. To that end, preparatory 
sensitization meetings with commanders and police officers of all ranks in all stations 
in Dar es Salaam were conducted. The meetings were intended to inform and educate 
police officers about the nature of HIV incidence study and the HIV vaccine trial 
project. In addition, information leaflets about what the study was all about were made 
available to workshop participants in a national language (Kiswahili).  
 
After these preparations, HIV Vaccine Immunogenicity Study (HIVIS03), a phase I/II 
trial was conducted among police officers in Dar es Salaam, and the first volunteer was 
vaccinated on 27 February 2007. The HIVIS03 was a collaborative research 
programme that involved Muhimbili University of Health and Allied Sciences 
(MUHAS) in Tanzania, the Swedish Institute for Communicable Disease Control 
(SMI) and Karolinska Institutet (KI) in Sweden, the University of Munich, Germany, 
and the University of Cape Town, South Africa, as well as the Walter Reed Army 
Institute of Research (WRAIR) in the US. The study received support from the 
European Union (EU), the Swedish Embassy in Dar es Salaam, and the European and 
Developing Countries Clinical Trials Partnership (EDCTP). The HIVIS03 trial further 
built up on the results of an earlier phase I HIV01/02 trial that was conducted among 40 
individuals in Stockholm, Sweden and which showed that the candidate 
Deoxyribonucleic acid (DNA)- Modified Vaccinia Ankara (MVA) vaccine caused mild 
and tolerable vaccine-related events [84] as well as being capable of eliciting good 
immune responses [85]. This study involved the experiences of recruitment and 
participation in the follow-up trial in Tanzania, HIVIS03. The vaccines used in the 
HIVIS03 trial were found to induce strong and broad immune responses among the 
vaccinated Tanzanian volunteers with priming with DNA and boosting with MVA [86].  
 
Based on the results from HIVIS03, another phase II HIV vaccine trial has been started 
in May 2010 to further explore the best HIV-1 DNA vaccine delivery method. This is a 
collaborative project between Tanzania and Mozambique (TaMoVac-1). The trial sites 
are based in two cities, Mbeya and Dar es Salaam. In Mbeya, the volunteers are 
recruited from the general population, while in Dar es Salaam they are recruited from 
the police force, prison force and youths. All the recruited volunteers are at low risk of 
HIV infection. Another TaMoVac-II trial is planned to start in April 2012 in Tanzania 
and Mozambique to further optimize DNA delivery using novel methods like 
electroporation, and also to further document the immunogenicity and safety of the 
vaccine.   
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1.5 RATIONALE 
In Tanzania, motivations for and barriers to participation in HIV vaccine trials have not 
been studied. For future HIV vaccine trials to succeed, it is important to understand the 
potential study participants in terms of knowledge, attitudes and their perceptions. 
General misconceptions about the HIV vaccines [5, 14, 20, 28, 34, 37, 39, 52] can 
prevent people from participating in any vaccine study. Such misconceptions may even 
interrupt scientific efforts towards prevention of other infections in the future as well as 
acceptability of a newly developed vaccine for other diseases. Therefore, studies on the 
existing knowledge, attitudes and perceptions towards HIV vaccines, norms, and risk 
behaviour are very important during phase I/II HIV vaccine trial implementation. This 
thesis provides contextual information to understand motivations and deterrents for 
participation in an HIV vaccine trial in Tanzania. Understanding this scenario is crucial 
to gain knowledge on the “motivations to participation in an HIV vaccine trial” among 
the Tanzanian‟s police officers who took part in the studies. The studies also provide 
unique information on the uptake of the current HIV prevention efforts within the 
police force in Dar es Salaam, Tanzania. 
 
1.6 AIM AND OBJECTIVES 
1.6.1 Aim 
To examine the motivations and deterrents for participation in preventive HIV vaccine 
trials 
 
1.6.2 Objectives (I-IV)  
I. To determine factors associated with willingness to volunteer in a phase I and II 
HIV vaccine trial among police officers 
II. To examine how police officers reason around their decision to volunteer for 
the HIV vaccine trial. 
III. To explore reasons for declining to enrol in the HIV vaccine trial after 
randomization among eligible volunteers.  
IV. To evaluate experiences of volunteers who participated in phase I and II vaccine 
trial.  
 
1.7 THEORETICAL MODEL 
This thesis focuses on different aspects of public health such as health promotion, 
disease prevention and evaluation of effectiveness of the programme intervention. 
Therefore, it is important to apply a model that can provide scope to analyze the 
knowledge, perceptions and cultural issues involved in the participation in an HIV 
vaccine trial in an African cultural context. In this regard, participation in an HIV 
vaccine trial is a health promotion issue and an important step towards prevention of 
HIV transmission (participating in the trial to develop a preventive vaccine). Thus, 
participation in an HIV vaccine trial should be examined (motivations and deterrents), 
evaluated and finally, the intervention points should be identified to aid the future 
design of clinical trials in a Tanzanian setting. 
 
1.7.1 PEN-3 Model 
PEN-3 is an acronym of the three components of each dimension (domain) in the 
model (Figure 1) that I will describe later. The PEN-3 model is a model that was 
developed and was first published in 1989 to be used in planning and evaluating 
culturally appropriate health interventions [87-88] in African settings. The model offers 
scope within which socio-cultural meanings can be cross-examined. It is also designed 
to put much more focus on the voices of the community, which form the basis of all 
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health interventions [87]. The model has been used to prioritize interventions aimed at 
HIV/AIDS prevention, care and support in Africa [88], HIV and AIDS-related stigma 
in the context of family support and race in South Africa [89], and in decision making 
on malaria treatment for children under five years among mothers in Nigeria [90]. The 
PEN-3 model is useful because it can be modified and extended as needed to fit 
different target cultures [91]. 
 
The model consists of three domains, each with three components. These domains are: 
Cultural empowerment; Relationships and expectations; and Cultural identity (Figure 
1). 
Figure 1. Pen-3 Model
CULTURAL 
EMPOWERMENT
Positive
Existential
Negative
Perceptions
Enablers
Nurturers
Person
Extended Family
Neighborhood
RELATIONSHIPS & 
EXPECTATIONS
CULTURAL 
IDENTITY
 
 
Cultural empowerment 
Within the cultural empowerment domain, Airhihenbuwa [87] argues that in every 
community, in every family, in every individual, there is tripartite entity of the 
following components: 
Positive: values and relationships that promote the health behaviour of interest. 
Existential: qualities of culture that make that culture unique; mostly ill understood by 
outsiders and often blamed for programme failures. 
Negative: the conventional objectives of programme interventions that focus on what is 
wrong that should be changed. 
 
Relationships and expectations:  
According to Airhihenbuwa [87], the influence of family, kin, and friends is important 
in nurturing individual behaviour. This emerges from the relationships and expectations 
that exist in any culture. The relationship and expectation domain is influenced by the 
following components [87-88]: 
Perception - knowledge and belief, values, in decision-making that are focused on 
either persons or groups, highlighting the complementarities of emotions and rationality 
in behaviour outcomes.   
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Enablers - resources and institutional support, socioeconomic status, and wealth (assets 
over liabilities) as measures of resources and power, and costs and availability of 
services. 
Nurturers - supportive and/or discouraging influences of families and friends including 
eating traditions, community and events, spirituality and soul, values of friends (e.g. 
alcohol consumption), and marriage rules and expectations. 
 
Cultural identity 
The above three components of cultural empowerment (positive, existential and 
negative) interact and co-exist with those of relationships and expectations 
(perceptions, enablers and nurturers) to define the individual and his or her cultural 
identity. The three components of the cultural identity domain are: 
Person – the degree to which the person may be dealing with the notion of double 
consciousness during programme interventions [87-88].  
Extended family – the degree to which the family network allows different persons 
within the family to influence key decisions in the family. Family relationships and 
responsibilities form the basis for communication on which preventive health 
programmes should be founded [87] . 
Neighbourhood – the capacity of a geographically and/or ideologically defined group 
(community, village, congregation, etc) to influence decisions for its collectives [87]. 
  
Cultural identity is the intervention point of entry because the question of identity is 
central in finding solutions to health problems [87]. The model gives scope in which 
the range of cultural values can be encouraged, acknowledged and/or discouraged by 
project implementers.  
 
1.7.2 Application of PEN-3 model in HIV vaccine trial participation 
This model has been loosely adapted in the present study to explain the phenomenon of 
participation in an HIV vaccine trial. The use of the PEN-3 model in the present study 
will help when responding to the question, “What motivates participation in HIV 
vaccine trials in a Tanzanian context?”  
 
The PEN-3 model will be used to organize the main results into categories specific to 
the components of cultural empowerment & relationships and expectations domains. 
The following is a description of how the components of the Cultural empowerment 
domain are applied in HIV vaccine trial participation:  
 Positive is the knowledge, values and/or beliefs that promote participation in 
HIV vaccine trials 
 Existential refers to cultural values among the community members that are 
somehow unique and that researchers may not be aware of in relation to 
participation in HIV vaccine trials, for example the opinions of significant 
others. 
 Negative focuses on what is wrong that should be changed in order to promote 
participation in HIV vaccine trials. 
 
Moreover, the components of the relationships and expectations domain are applied to 
HIV vaccine trial participation as described below:  
 Perception refers to knowledge, beliefs and values that motivate people to 
volunteer for an HIV vaccine trial. 
 Enablers are institutional support mechanisms available to facilitate 
participation in HIV vaccine trials 
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 Nurturers are elements of support and /or discouraging influences of significant 
others towards participation in HIV vaccine trials. 
The components from both domains are integrated in the presentation of the results in 
the thesis.  
 
Appendix II summarizes the selected results from each objective. 
 
The cultural identity is a point of intervention. In HIV vaccine trials, some of the 
interventions will be directed at the individual level. For example, the precise 
information about the phase I/II HIV vaccine trial should focus on individual volunteers 
while the misconceptions and rumours should be addressed at both community and 
individual levels. Information targeting families or close members of the family 
(extended family) may be used to tailor recruitment strategies. So, cultural identity 
domain will be discussed along with other components and will be also addressed in 
the recommendations. 
 
In this way, the model constitutes a suitable framework to synthesize the findings in an 
understandable manner for the trial implementers, leading up to recommendations for 
designing future trials in a similar context. Thus, the range of cultural values can be 
encouraged – (positive responses towards participation in the trial), acknowledged – 
(existential or nurturers in the community), or discouraged – (negative responses 
towards participation in the trial) by the HIV vaccine trial implementers. 
 
Therefore, a decision to participate in the future HIV vaccine trials in this context 
where this study was conducted will be based on where the intervention [education] 
should take place because health education can be used to reinforce long-term cultural 
beliefs at appropriate levels. That is, at a personal, extended family, neighbourhood or 
community level.   
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2 METHODS 
2.1 CONTEXT AND POPULATION 
2.1.1 Setting 
All studies were carried out in Dar es Salaam, Tanzania. Tanzania is situated in East 
Africa, immediately south of the equator, with an area of 947 300 square kilometres 
and a population of 42 746 620 million people [92]. Administratively, it is divided into 
26 regions. The Dar es Salaam region, in the east coast of Tanzania, has an area of 
1 393 square kilometres and a population of 3.207 million according to 2009 estimates 
[92].  According to DSS data [93], administratively, Dar es Salaam is divided into the 
municipalities of Ilala, Temeke and Kinondoni. Dar es Salaam has a mixture of more 
than 120 ethnic groups from all parts of Tanzania but originally only one group 
(Zaramo) inhabited the area.  The majority of the population are Muslim (70%), and the 
rest are Christian (30%). Kiswahili is the major language. A large portion of people in 
the region work for small businesses or do manual labour (both skilled and unskilled); 
and a few have office jobs. The region has three municipal-government hospitals, a 
national hospital (Muhimbili), which is also a large public university teaching hospital, 
private hospitals and health centres as well as not-for-profit health organizations [93].  
 
 
 
 
 
 
Figure 2. Location of Dar es Salaam, adapted from DSS site map, Tanzania 
Source: http://www.idrc.ca/ev_en.php?ID=43009_201&ID2=DO_TOPIC  
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Table 1. Selected health and development indicators in Tanzania 
 Indicator Figure 
1 Population growth rate (%, 2011 estimates) 2  
2 Birth rate (births /1000 population, 2011 estimates) 32.64  
3 Death rate (death/1000 population, 2011 estimates) 12.09  
4 Infant mortality (deaths/ 1000 live births, 2011 estimates) 66.93  
5 Life expectancy at birth, both sexes (years) 53 
6 Total fertility rate (children born/woman) 4 
7 Sex ratio (male(s)/female) 1.03 
8 Literacy level (%, 2002 census) 69.4 
9 Population living in urban areas (%) 26 
10 GDP per capital (Purchasing power parity – PPP (2010 est.)) 1,500 
11 GDP (PPP) (billion, 2010 estimates) 62.22  
12 GDP (Real growth rate  - 2010 est. %) 6.4 
 
Source: https://www.cia.gov/library/publications/the-world-factbook/geos/tz.html  
 
2.1.2 Health system 
Tanzania has a well-developed, albeit basic health care delivery system that is 
organized at three levels – primary, secondary and tertiary. The primary level consists 
of dispensaries, health centres and district hospitals. The secondary level consists of 
regional hospitals with six tertiary hospitals in the country [94]. MNH is one of the 
tertiary hospitals based in the City of Dar es Salaam. The referral system of patients 
from one level to another follows the skills that are required to address the problems 
of the patients. HIV prevention and AIDS care and treatment services are integrated 
into all levels through policy and technical support from the Tanzania Commission 
for AIDS (TACAIDS) and the National AIDS Control Programme (NACP) 
respectively. TACAIDS was created by a parliamentary statute in 2001 and is 
mandated to provide strategic leadership, coordinate multisectoral response and 
perform monitoring and evaluation activities, including research, resource 
mobilization and advocacy. Among other activities, the NACP, under the Ministry of 
Health and Social Welfare (MOHSW), conducts sentinel surveillance to provide 
updated estimates of selected basic demographic and health indicators [68]. In 2005, 
the United Republic of Tanzania under the MOHSW launched a national HIV vaccine 
framework to guide vaccine trials research in Tanzania. This framework is 
comprehensive in the sense that it highlights all the essential requirements for 
conducting clinical trials [95]. According to this framework, emphasis has been also 
on socio-cultural and political challenges in conducting HIV vaccine trials.   
 
2.1.3 The HIV epidemic in Tanzania 
Similar to many other sub-Saharan African countries, Tanzania is facing challenges in 
controlling the HIV epidemic. Since the first cases of AIDS were recorded in Tanzania 
in 1983 [96], enormous efforts have been made to control the epidemic. This includes 
promotion of condom use and behaviour change [70]. Despite the efforts, the number 
of HIV-infected individuals continued to increase until 2006 when prevalence started to 
stabilize in most regions in the country [68].  
 
Dar es Salaam, the region of interest in this study, has the second-highest prevalence of 
HIV in the country [68]. Unlike other regions of Tanzania, Dar es Salaam draws 
attention in respect to HIV/AIDS in various ways. Most people are exposed to HIV 
prevention messages through mass media; consequently, there is increased public 
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awareness of HIV/AIDS and attitudes are more open. Nevertheless, in this most 
populous city, previous studies have shown a high HIV prevalence. For instance, the 
sero-prevalence among hotel workers was 10.4% in 1990 [97]; and was 13% among the 
police force in 1995 [75]. The prevalence is still high (9.3%) in this city[68]. Women 
aged between 30 and 39 years had an estimated prevalence of between 9.5 and 10.4 in 
2008. The overall prevalence for both men and women in the age group of 15-49 is 5.7 
[68], a group that is reproductively important, and also the most economically 
productive.  
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Figure 3. Distribution of HIV prevalence in Tanzania by region - 2008 
Source: Tanzania HIV and Malaria Indicator (THMI) Survey – NBS, TACAIDS and 
Macro International, 2007-2008 
 
Table 2. Selected HIV/AIDS indicators 
1 Indicator Tanzania  Sub-Saharan 
Africa 
Global 
2 % prevalence among adults (15/49 years) 5.6 5.0 0.8 
3 Adults and children living with HIV  (million) 1.4  22.5 33.3 
4 AIDS-related deaths among adults and children 110 000 1 400 000 1 800 000 
5 Adults and children newly infected with HIV 100 000 1 800 000 2 600 000 
6 Access to anti-retroviral drugs among people 
eligible for treatment (Adult coverage %) 
32 37 36 
 
Source: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf  
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2.1.4 Study population 
A total number of approximately 3 000 police officers, 20% of them female, made up 
the police force in Dar es Salaam during data collection. The region has 32 police 
stations, all of which were involved in the Tanzania-Sweden collaboration 
(TANSWED) project which recruited approximately 1 300 police officers from all 
stations to determine the current prevalence of HIV infection in 2005 - 2006.   
 
The following section presents the flow of activities and series of studies from 
preparation to the evaluation of phase I/II HIV vaccine trials.   
 
 
 
Figure 4. Activities, population and study time points 
 
2.2 STUDY DESIGNS AND PARTICIPANTS   
2.2.1 Study I 
Participants were recruited from a pool of approximately 3 000 police officers (Figure 
4). Approximately 1 300 of these voluntarily participated in sensitization meetings to 
learn basic information about HIV infection at the national and individual level. They 
also took part in an HIV prevalence study. These meetings were held in the police 
stations by a field team consisting of doctors, nurses and counsellors from MUHAS and 
MNH together with collaborators from the police force, a medical doctor and a nurse 
from the Health Unit in the police force. Questions and answers led to extensive 
discussion on various concerns about HIV/AIDS, which were addressed by the field 
team. The field team gave the police officers detailed information about the aims of 
HIV/AIDS and HIV vaccine trial project. During the meetings, information leaflets 
were distributed. After each meeting, the participants were voluntarily invited to take 
and read the consent form which described all the details of the studies, and get back to 
the nurse counsellors if they wished to take part in the studies. After understanding the 
details of the studies, all of them returned the forms either with the intention of 
participating or not participating in the studies. Those who wanted to participate in the 
studies signed the consent form, were interviewed on social and behavioural issues 
(Questionnaire 1), and then received voluntary pre-test counselling proceeded by HIV 
testing. In this interview, participants were also asked to indicate if they were willing to 
form a group of educators (core group) to educate other police officers about 
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HIV/AIDS and HIV vaccine trials following additional training. (A total of 408 signed 
for the core group membership). After two weeks, those who tested for HIV were 
contacted for post-test counselling and HIV test results, followed by second interview 
on vaccine knowledge, attitude and willingness to volunteer for the HIV vaccine trial 
study (Questionnaire 2). A convenience sample of 329 responded to both 
questionnaires, and was included in Study I.  
 
2.2.2 Study II 
Study participants were recruited from the group of participants who were interested in 
educating others (the 408 members of the core group) about HIV/AIDS and HIV 
vaccine trials after a detailed workshop. This workshop was more informative than the 
sensitization meetings in the sense that it was conducted in a venue outside the police 
stations on Saturdays, with facilities such as powerpoint presentations, and handouts 
about the HIV vaccine trials (frequently asked questions).  The details of the magnitude 
of HIV/AIDS globally, regionally and nationally; historical background of the available 
vaccines such as polio, measles; reports of ongoing HIV vaccine trials in the world and 
phase I and II trial in Sweden were discussed with the workshop participants. In 
addition, the field team provided information on the benefits and risks of taking part in 
the planned phase I and II HIV vaccine trial among police officers in Dar es Salaam. 
Such benefits were: complete physical check-up; free medical services and referral to 
credited health centres if taken ill during the trial; follow-up visits and regular HIV 
testing. Possible risks such as unknown preventive effect of the vaccine were also 
discussed. The team clarified the inclusion criteria, including the age limit of between 
18 and 40 years (HIVIS03 requirement) and contraceptive measures to avert pregnancy 
throughout the trial period. The participants were asked to share the education obtained 
from the workshop with colleagues at work. The workshop organizers provided the 
volunteers with the option of giving their contact details before leaving the venue for 
internal use only. (Through this process, a total of 265 participants from repeated 
similar workshop registered that they would like to volunteer for the HIV vaccine trial). 
A month after the workshop, a purposive sample was drawn from the workshop 
attendees for Study II. Groups of diverse membership with respect to age, sex, rank, 
location of the police stations, marital status and whether the participant played a care- 
giving role for a relative suffering from AIDS were formed for focus group discussions 
(FGDs). Except for the care-giving role group, stations with less than four participants 
who did not fit into the pre-determined characteristics of the groups were excluded 
from the sampling frame. A total of 66 participants were included from the stations that 
met the inclusion criteria.  
 
Stepping-stones to Study III and Study IV 
Special sessions about the vaccine that was being tested were organized and general 
information relating to the implementation of phase I and II HIV vaccine trials such as 
trial duration, required investigations, procedures, rules and the number of study visits 
including what the volunteer should expect at each visit was given to the 265 potential 
volunteers in groups of 50-60. Pedagogic illustrations were used to emphasize 
understanding, for example the amount of blood needed for the tests as compared to the 
total blood volume in a healthy individual. A comprehensive checklist of who was 
eligible for such trials was discussed. Those who considered themselves eligible for the 
trial according to the checklist were asked to confidentially register their contact details 
for future screening [complete medical and behavioural risk assessment]. On different 
occasions, those who met the eligibility requirements were invited for individual 
screening at the trial site. Before the screening took place, each individual signed part 
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one of the informed consent form, a prerequisite for enrolment in the trial. The 
screening involved: clinical history and examination; HIV counselling and testing; 
safety laboratory tests; screening for syphilis and hepatitis B infections; blood for 
haematological and clinical chemistry, and urine collection for pregnancy test among 
females. Potential volunteers were also interviewed by the study nurse about their risk 
behaviour, for example the number of sexual partners they had had in the last six 
months and whether condoms were used. Two weeks later, they signed part two of the 
informed consent form to confirm their enrolment in the HIV vaccine trial and follow-
up if they skipped the planned schedules. This procedure of signing two parts of the 
informed consent form was stated in the original project protocol. During this second 
visit, all laboratory results in line with fulfilling the inclusion criteria were reviewed 
and the volunteer was assessed to make sure that he or she had understood the 
objectives of the study. A total of 79 participants were randomized into the trial. 
Nineteen skipped or withdrew before the first injection and were replaced to obtain a 
total of 60 vaccinees (Figure 4).  
 
2.2.3 Study III 
Studies III and IV were affiliated with the HIVIS03 trial. Informants for Study III were 
recruited from the 19 eligible volunteers for the phase I/II trial who withdrew from the 
trial after randomization (19/79). The sample was all-inclusive of the participants who 
declined to enrol in the trial. The author of this thesis, who was also part of the 
recruitment team, contacted the potential study participants by mobile phone, briefed 
them about the aim of the present study, and asked whether they were willing to share 
their reasons for declining to enrol in the HIV vaccine trial. Of the 19 targeted 
participants, 14 (74%) agreed, were accessible, chose to meet the author at their 
workplace and participated in the study.  
 
2.2.4 Study IV 
As stated earlier, the HIVIS03 project randomized 79 volunteers in total, but 19 
withdrew after randomization (see above). The remaining 60 volunteers, 15 (25%) of 
them being women, enrolled fully in the trial and proceeded with the scheduled follow-
up trial visits (Figure 4). Therefore, the participants in Study IV were drawn from the 
volunteers who enrolled and completed the trial schedules. The recruitment of these 
participants started towards the end of the vaccination procedures; two announcements 
about this study were made during regular workshops with the volunteers, telling them 
that they would be invited to share their experiences during the trial with the 
researchers. Volunteers who took part in an earlier interview after the third DNA / 
placebo vaccination [98] were excluded from the sampling frame because we wanted to 
gain the shared perspectives from those who were never interviewed. Before the actual 
invitation to FGDs, the first author grouped the potential participants by gender and 
marital status. The number of participants per group ranged from 7-11 which followed 
the recommended size for focus group discussions of 3-12 people [99-100]. A total of 
35 participants were included in the study. 
 
2.3 DATA COLLECTION TOOLS 
2.3.1 Structured interviews [Questionnaire] (Study I) 
Whereas unstructured interviews contain a number of open-ended questions, semi-
structured interviews lie somewhere between the structured and unstructured types, 
containing elements of both, with some questions being closer to structured interviews, 
and others closer to unstructured ones [101].  
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In Study I, peer-reviewed and pre-tested questionnaires containing both close- and 
open-ended questions were used to collect data. The first questionnaire was used to 
gather basic information on knowledge, attitudes to HIV and AIDS, sexual practices 
and was assessed by „yes‟, „no‟ or „I don‟t know‟ options. The second questionnaire 
comprised questions on vaccine knowledge and attitudes to vaccine trials. Knowledge 
about how a vaccine works was assessed by asking an open-ended question; 
categorized as either „right‟, „not right‟ or „I don‟t know‟ by the interviewer; attitudes 
towards vaccines and willingness to volunteer in HIV vaccine trials were assessed by 
using „yes‟, „no‟ or „I don‟t know‟ responses. The reasons for the given responses on 
willingness were further explored by using open-ended questions that were categorized 
accordingly. Both questionnaires were administered in face-to-face interviews by 
trained nurse counsellors. The nurses‟ expertise in health issues enabled them to give 
immediate counselling to the study respondents after filling in the questionnaire. The 
semi-structured interview was used to collect data because the nature of the study 
design involved knowledge facts and scope for immediate intervention 
(counselling/education) when required. The PhD candidate (EAMT) also took part in 
data collection and counselling. 
 
2.3.2 FGDs (Studies II & IV) 
Focus group is an inquiry that uses interview in groups of people who have experiences 
or conditions that are of interest to researchers [99]. The group interviews are 
stimulated by the interaction between the participants, from which researchers discover 
how participants think and feel about a particular issue [99, 102]. We therefore used 
FGDs because they are typically designed to elicit normative views and perceptions 
[103]. They also preserve group norms, richness of the information, and groups‟ 
perspectives in terms of collective judgements [104]. A topic guide is often used to 
moderate the discussion.  
 
In study II, the number of the participants per group ranged from four to twelve. A 
topic guide comprising general socio-demographic background information was 
provided and two main research issues were asked: (1) “Can you tell me your views 
about the problem of HIV and AIDS in the police force?”  (2) “What are the cultural 
norms, views and opinions among police officers that may influence willingness to 
volunteer in an HIV vaccine trial?” In the present study, we focus on the cultural 
norms, views and opinions among police officers that may influence willingness to take 
part in HIV vaccine trial. All FGDs were conducted in a location of the participants‟ 
own choice at the police stations. Two trained and experienced moderators 
interchangeably moderated the discussions, which were audio-recorded and lasted 
between 25 and 71 minutes. 
 
In Study IV, the number of group participants ranged from seven to eleven, and one 
question was asked: “Can you tell us your opinion on changes that occurred during the 
vaccination period?” This question was followed by probing questions. The discussion 
was held in a venue at the trial site and I (EAMT) was the moderator, having been 
trained and experienced in moderation skills. The discussions lasted between 79 and 
115 minutes.  
 
2.3.3 Face-to-face interviews (Study III) 
An interview is a data collection tool used to explore the „insider perspective‟; to 
capture, in the participants‟ own words, their thoughts, perceptions, feelings and 
experiences either face-to-face, over the telephone or on the Internet; and the tone of 
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the interview is generally informal and conversational [105]. It is informal and 
conversational in the sense that the researcher uses an interview guide to explore and 
understand the world from the participant‟s perspectives. A face-to-face interview was 
considered appropriate for data collection because it can elicit personal opinions about 
sensitive issues, and will reveal the topic and importantly, the research question was on 
personally oriented experiences. 
 
In Study III, face-to-face interview with a semi-structured guide was used to collect 
data. The interview guide contained the following statements: “I understand you are 
among the volunteers who were randomized in an HIV vaccine trial; however, later you 
decided not to continue with the planned visits for the vaccinations. Can you explain to 
me the reasons for not continuing with the scheduled vaccinations?” This question was 
followed by a probing set of questions related to the responses. All interviews were 
audio-recorded except one due to a noisy environment. The interviews lasted for 10-30 
minutes, excluding the conversations before and after the audio recording. 
 
2.4 DATA ANALYSIS 
2.4.1 Statistical analysis (Study I) 
The first step was to merge the two questionnaires by using the respondents‟ exclusive 
study numbers. Frequency distribution of all social demographic variables (sex, age, 
marital status, religion, education, number of children, housing, ranks and work 
stations) and other independent variables was performed. All the social demographic 
variables and other dichotomous or categorical variables whose responses were 
represented by options of „yes‟, „no‟ and „I don‟t know‟ were cross-tabulated for 
willingness to volunteer in an HIV vaccine trial, and Pearson Chi-square was displayed.  
 
For the subsequent analysis, we created new variables. For example: „single/separated‟ 
and „widowed‟ were merged into „single‟ and compared with „married‟. All other 
independent variables were also merged. For example: Do you think Tanzania should 
be a partner in developing HIV vaccine?: „yes‟, „no‟, and „I don‟t know‟. We repeated 
the cross-tabulation and test for willingness after merging and only marital status 
changed to non-significant in the Pearson Chi-square test. All variables that were 
significant with the Pearson Chi-square except marital status were significant in the 
final model.  
 
We applied binary logistic regression to analyze willingness and the associated socio-
demographic characteristics, knowledge, attitudes, self-perception of risk and risk 
behaviours. The willingness to volunteer (WTV) for the HIV vaccine trial was assessed 
by „yes‟ and „no‟ choices. Binary logistic regression was performed to estimate the 
odds ratio (OR) and 95% confidence interval (CI) of factors associated with WTV for 
the HIV vaccine trial. Missing responses were excluded and non-significant results 
were not reported. Statistical analysis was conducted using SPSS 15.0 for Windows 
(SPSS, Inc Chicago, IL, USA). Open-ended questions such as the reasons given for 
volunteering or not volunteering for the trial were analyzed using a content analysis 
approach. 
 
2.4.2 Interpretive description (Study II and Study IV) 
Interpretive description is an inductive analytic approach designed to create ways of 
understanding clinical phenomena that yield applications implications [106]. The 
method relates to other qualitative methods in the sense that it borrows from some 
aspects of grounded theory, naturalistic inquiry, and ethnography, drawing values 
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associated with phenomenological approaches [107]. As other qualitative methods of 
analysis, ID uses similar process such as coding, categories formation and theme(s). 
Primarily, ID aims to answer questions of relevance to clinical disciplines in which 
understanding and focus are considered crucial.  
 
The audio-taped FGDs were listened to after each FGD to help design the probes for 
the next FGD; transcribed verbatim and translated from Kiswahili to English. The main 
author (EAMT), a bilingual speaker of Kiswahili and English, read all the transcripts 
several times to understand the data set and to identify ideas, patterns and codes on the 
margins of the transcripts. The codes were then read and compared. To increase 
validity and ensure quality, data were inductively coded separately and discussed 
between two researchers in both Study II and Study IV.  Through an interpretive 
process, the categories were formed and compared against the FGD transcripts to 
ensure that interpretive analysis reflected the raw data content. The underlying 
meanings in the data set led to emerging themes. Finally, all authors read the analysis 
and agreed on the emerging theme(s). The preliminary findings were presented and 
discussed with the trial team and the study participants on different occasions. The 
discussion provided more insight on the data, leading to a review of the categories and 
the theme(s). In both studies, quotes were used to reflect the voices of the participants 
in the studies.  
 
2.4.3 Content analysis (Study III) 
In qualitative research, content analysis can be approached in either latent or manifest 
form. Latent analysis is the analysis of what the text talks about, relationship aspects 
and involves interpretation of underlying meanings of the text while manifest analysis 
involves analysis of visible obvious components of the text [108]. According to 
Graneheim and Lundman [109], both forms focus on selecting the unit of analysis, 
meaning unit, codes; categories and themes; the common terms used in content 
analysis. Meaning units, words are sentences or paragraphs containing aspects related 
to each other through their content and context; A code is a tool which can be assigned 
to a phenomenon and should be understood in relation to the context; A category refers 
to a group of content that shares a commonality and mainly forms a descriptive level of 
content and can thus be seen as an expression of the manifest content of the text. The 
category can be divided into sub-categories. A theme can emerge as a thread of 
underlying meaning through condensed meaning units, codes or categories on an 
interpretive level. 
 
In Study III, content analysis was used and each interview was viewed as a unit of 
analysis. Statements or paragraphs that related to the same central meaning were 
grouped as a meaning unit. The text was reduced by condensing the meaning. Although 
sometimes we used different words, the essence was preserved. Codes were created and 
used as tools to interpret the text. Sub-categories and categories were constructed from 
the group of codes that had common ideas. A theme emerged through the condensed 
meaning unit, codes, sub-categories and categories. 
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Summary of studies and research questions 
 
Domains                             Research questions             Data collection & Population      Articles  
Interview based 
questionnaire among 
329 police officers
Face to face Interview  
among 14 of  19 drop 
outs 
FGDs  among 35 of 
60 volunteers who 
participated in the 
trial
FGDs  among 66 police 
officers
I
II
III
IV
What are the 
experiences of the 
HIV vaccine trial 
volunteers who 
completed the 
trial?
What are the reasons 
for dropping out 
during the HIV 
vaccine trial?
What are the factors 
associated with 
willingness to 
participate in HIV 
vaccine trial studies?
During 
the 
trial
Post
-trial
Pre-
trial
 
Figure 4. Domains, research questions, data collection and list of articles 
 
2.5 ETHICAL CONSIDERATION 
Ethical permits for all studies were obtained from the institutional review bodies, 
namely MUCHS IRB dated 11th November 2004; National Institute for Medical 
Research (NIMR) Ethics Committee- NIMR/HQ/R.8a/Vol.IX/410 dated 30 January 
2006; and Muhimbili University Ethics Committee dated 20 April 2006. Permission 
letters from the police high authorities were obtained. Ethical principles were adhered 
to throughout the studies. Potential study participants signed informed consent forms 
describing all the study components before engaging in the studies. 
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3 MAIN FINDINGS  
The PEN-3 model is used to organize the main findings into categories which are 
specific to the components of cultural empowerment & relationships and expectations 
domains.  By applying the components of PEN-3 model; for example, the presence and 
influence of significant others in the decision to volunteer in an HIV vaccine trial are 
perceived from the start to the end of the HIV vaccine trial. The perception of 
significant others co-exists or operates separately with fear of unknown side-effects 
from an experimental vaccine. However, participants consistently see opportunities in 
the trial leading up to positive perception about the trial. 
 
Existential nurturers: Facing resistance of significant others to participation in 
HIV vaccine trials (Study I, II, III, IV). 
Willingness to volunteer for an HIV vaccine trial was significantly associated with 
intention to tell others (sexual partners, friends, family members, relatives or parents) 
about one‟s decision (OR, 36.48 (95% CI: 15.07-88.28), and the reason to share the 
information was to provide a safety-net should the vaccine turn out to be harmful to the 
volunteers (I).  
 
On the contrary, participants speculated that telling others about their intention to 
volunteer in an HIV vaccine trial would be negatively received (II). Consequently, 
those who consulted friends about their intention to volunteer in a trial encountered 
resistance that forced them to weigh their decision against the friends‟ opinions. Others 
decided not to participate in the trial to avoid being abandoned: 
“Every time I told my colleague policewomen about this [the HIV 
vaccine trial] they challenged me. ... „Go first and get it [the vaccine] 
because you are HIV positive.‟… So I decided to quit…” (Young 
policewoman 2, Group 1) – II. 
 
Sharing of the information within the social networks was important because of the 
existing social relationships and dependencies (parents expecting their children to 
support them in old age). However, participants said that parents have a strong 
influence on the lives of young people, and young people saw themselves as an asset 
for the future with responsibilities towards their parents. These young people, men in 
particular, speculated that parents would expect them not to take part in the trial since 
they depend on each other. The parents were said to worry that the vaccine could cause 
side-effects as indicated in the conversation below: 
“Some of us are taken care of by our parents. Now what would your 
father say if you get problems? They [parents] will query: „Don‟t you 
know that we depend on you?” (Young policeman 6, Group 4) – II.  
 
They further suspected that pregnancy norms would be the source of fear among the 
parents:  
“A parent can tell you that: „If you are vaccinated and get married you 
will not get children‟. He or she thinks if you get the vaccine you will not 
get a child…” (Young policeman 1, Group 4) – II. 
 
These concerns emerged as realities (III). Those who decided to volunteer in the HIV 
vaccine trial had to withdraw because they did not receive approval of significant 
others. Simply, participants were obliged to respect the opinions of significant others to 
maintain the existing social relationships. Particularly, the young men realized that 
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enrolling in the HIV vaccine trial was counter-productive. They felt responsible and  
needed to „be the insurance for their parents‟ despite the fact that they were interested 
in enrolling in the trial. The following discourse explains: 
“When I told my mother about that [vaccine trial], in brief she was 
shocked! … On top of that I‟m the only son remaining in our family; the 
rest passed away… She insisted I should stop where I reached. That 
means I should stop. I asked her why? She said: „that is what I am saying, 
if you are going against, it will be your decision and what I have told you, 
that is it‟. So, I thought of that… That was the end of the exercise, but I 
was not happy to stop there” (Informant 13, man) - III. 
 
Unlike men, women were mostly influenced by their intimate male sexual partners. 
One woman was indirectly warned by her fiancée and she couldn‟t convince him. 
Another woman explained that her fiancée forbad her to enrol straight away. She felt 
bad about it, but she could not go against him as it would spell the end of her marriage. 
She said: 
“…my fiancée did not accept it completely! And he warned if I enrol in 
the trial our relationship would end; even though he had already paid a 
dowry, he would postpone our marriage plans… I felt bad because I had 
already committed myself with that relationship and I saw there is no way 
to convince him” (Informant 11, woman) - III. 
Similarly, those who enrolled in the trial and stayed on until the end (IV) continued to 
faced resistance from significant others. The family, where indeed supportive networks 
should be established, was instead experienced as a discomfort zone during the trial. 
Several participants noted that close family members such as parents, sexual partners 
and blood relatives demonstrated attitudes of mistrust over vaccine safety. Some men 
reported that their wives were distressed by comments from local people about their 
husbands taking part in a harmful study. Under such circumstances, the husbands 
tirelessly put pressure on educating their wives. Several opted to share the information 
with their intimate friends, but not their mothers because of the perceived notion that 
mothers may have difficulties in understanding the purpose of the trial: 
“I tried hard to explain to my lover but when it came to the other side, the 
side of the parents… I didn‟t tell my mother this issue because I knew it 
would take time for her to understand…” (Man 3, unmarried, Group 2) – 
IV 
On the other side, those who shared their enrolment decisions with relatives felt 
abandoned. One man told us: 
“I tried to explain [about the trial] to my relatives. Truly, all of them 
threw me out of the line [discouraged me]... So, I am alone; they find its 
okay. When I phoned and told them that I have fever, they say: „You 
wait, go ahead!‟ [The relatives warned]. So those are their current 
responses. Now even if I have mild-fever, I don‟t call them” (Man 7, 
unmarried, Group 2) – IV. 
 
In this group, other participants sensed that the reaction from family members was 
more painful than the reaction from friends. For example, they noted that some parents 
were shocked after realizing that, without their knowledge, their sons and daughters 
were in the HIV vaccine trial. Overall, significant others‟ influence cut across all the 
four studies, and their influence is more negative than positive.  
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Existential perceptions: Sexual practices/ behaviour and reproduction concerns 
(Study I, II, III and IV) 
In Study I, participants would volunteer for an HIV vaccine trial because they had extra 
sexual partners and they perceived themselves at risk of becoming HIV infected. In 
Study II, participants feared having an HIV test to avoid knowing their HIV status, and 
they felt it was okay if they got HIV infection through unprotected sexual intercourse. 
They reasoned that getting HIV through unsafe sex involved pleasure unlike the 
vaccine which would bring pain. Married policemen explained why a fear of HIV 
transmission by unsafe sex was different from that of the vaccine: 
“There [in sexual intercourse] you enjoy. That is what it means. It is not 
like when you are being vaccinated. There [sex] you know you are 
straightforward enjoying. So it is right if I get infected” (Married 
policeman 7, Group 7)- II. 
Another one added: 
“You know with sex, it is imaginary. One goes thinking that he is safe 
and may be also my partner is safe. You see when doing sex, one does 
not know... That is the way it is, but sex and vaccine differ a little bit” 
(Married policeman 2, Group 7)-II. 
 
Sexual relationships were important for reproduction continuity; gender power 
relationships were perceived in the decision whether to volunteer for an HIV vaccine 
trial or not. Women feared that postponing pregnancy because of enrolment in the 
vaccine trial could be a major concern to their husbands and boyfriends: 
“The problem is with the family [husband], that is when it becomes 
difficult. I get the vaccine and my husband wants a child then ... I think 
problems will start there” (Older policewoman 1, Group 2)- II. 
 
“There is a problem with girlfriend and boyfriend. For example, with the 
boyfriend he could stay with a woman for a long time, outside marriage 
lock and he wants to have a child with her ... if she postpones, of course 
the friendship will end” (Older policewoman 4, Group 2) - II. 
 
They also raised personal doubts about their reproductive capacity and possibility of 
becoming infertile after taking part in the trial: 
“Is there any possibility for me to get a child? Won't they [the 
researchers] just destroy my gametes?” (Older policewoman 3, Group 2) - 
II. 
 
They also feared being stigmatized by others if they participated in HIV vaccine trials. 
 
In Study III, condom use and interference with reproduction continuity were the 
concerns among the drop-outs. They believed the rules in the vaccine trial were not 
in favour of their sexual practices. One participant expressed: 
“…they [researchers] presented it in this way: ‟you are not supposed to 
do sexual intercourse without a condom for a certain period. Then a 
woman should not conceive or get pregnant…That is the main reason for 
us to discontinue, and saying that „even if you will be given that vaccine 
will be there a feeling in your marriage relationship? It will only bring 
disturbance!” (Informant 3, man) - III. 
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In study IV, the norms of sexual practices were recognized throughout the discussion 
and condom use was found to be a valuable tool towards HIV prevention. Men insisted 
that risky sexual behaviour was part of their daily lives. Despite having multiple sexual 
relationships even after enrolling in the trial, the information and counselling in the trial 
helped them to change to safer sexual behaviour: 
“Those seminars helped us a lot because from the first vaccination, we 
were told that wearing a condom is really important. That one helped 
because some of us had multiple sexual partners… I mean, I do not have 
strange things [risk behaviour]...” (Man 6, married, Group 1)- IV 
Participants agreed that condom use was useful for both HIV and pregnancy 
prevention. However, others were confused whether to use condoms consistently with 
stable sexual partners during the trial. In some cases, stigma was attached to the 
postponement of pregnancy. Women felt that their friends believed that the HIV 
vaccine trial would had negative consequences on their reproductive health: 
“And another person suspected that I could not give birth because of the 
vaccine. I mean for example at the work place, aah, truly God helped us. 
We have come a long way and now we are breathing… They saw us as 
people who are infected with the virus...waiting to die and that confused 
us.” (Woman 1, married, Group 3)- IV 
 
Other participants felt traumatized by negative comments from colleagues (stigma) 
especially during illness episodes. 
 
Negative perceptions: Existing fear fuelled by mistrust of researchers in the trial 
(Study I, II, III and IV) 
Willingness to volunteers for an HIV vaccine trial, however; would be hindered by fear 
of potential side-effects from the HIV vaccine and suspicion of why the vaccine should 
be tested on Tanzanians only (I). Participants expressed another fear arising from the 
thorough medical check-ups that were a condition for inclusion in the trial (II). They 
feared these check-ups might reveal their HIV status or other life-threatening diseases. 
In addition, the fear was fuelled with the suspicion that the vaccine would have a 
negative impact on one‟s health status, such as their reproductive biology (II). Young 
women talked about the risk of becoming infertile after taking part in the trial: 
“There are some women without a child and other people tell them that 
following vaccination they will never conceive!” (Young policewoman 7, 
Group 1) – II. 
 
Some men suspected the vaccine could make men impotent. They also suspected that 
children might be born with abnormalities because of drugs such as oral contraceptives. 
They reasoned that similar effects could arise from the HIV vaccine:  
“People know exactly that children are being born with abnormalities 
because of drugs [contraceptives]. And now an HIV vaccine has arrived!” 
(Low ranking policeman 3, Group 6)- II. 
 
The fear of the vaccine was fuelled by mistrust of the researchers in this trial. 
Participants saw the researchers as people who were seeking to gain something from 
the research other than helping the research participants: They speculated that the 
researchers were hiding the truth about the effects of the vaccine: 
“They [researchers] are liars. They will plant virus on us! …Why don‟t 
they try with animals?” (Low ranking policewoman 12, Group 3) - II. 
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The attitude of mistrust seems to arise from the fact that the vaccine was imported into 
the country. The participants reasoned that if such a vaccine had been proven safe after 
testing on animals and then used on human beings elsewhere, why test it again on 
Tanzanian police officers? They argued that the researchers in the vaccine project 
might benefit financially from the trial: 
“They [the researchers] already got money from there [donors]. Now to 
prove they have done the job they are moving around here… A neighbour 
told me not to engage in the trial.” (Low ranking policeman 1, Group 6) – 
II.  
 
Also, fear of the vaccine‟s side-effect was one of the reasons for declining to enrol in 
HIV vaccine trial (III). For example, a newly married man decided not to continue  
because he was mostly concerned with the trial rules that seemed to interfere with his 
marriage intentions. He was worried about the effect of an experimental vaccine on his 
reproductive capacity even before fathering a child. He decided to postpone enrolling 
and gave priority to having a child. He narrated: 
“First, it was the vaccine on trial, and we were told that if we accept to 
participate in that programme we are not supposed to engage in 
penetrative sexual intercourse with any woman for a year to avoid its 
effects in pregnancy. At that time, I was doing another attempt in order to 
get a child!” (Informant 12, man)- III. 
Thus, his fear was mainly connected with reproduction continuity. 
 
In addition, informants were suspicious about the researchers‟ intentions. Some 
believed that the HIV vaccine could have side-effects that the researchers were not 
even aware of. One informant believed that the researchers were afraid of taking part in 
the trial because of uncertainty about the trial: 
“It may have negative effects in the future. You [researchers] insisted that 
the vaccine has no side-effects but it is not true. One day I asked one of 
you who facilitated the seminar that „who gets an HIV vaccine among 
you?‟ They said „we are not allowed to get that vaccine because we are 
service providers.‟ Don‟t you see that you are avoiding something?” 
(Informant 14, woman) -  III. 
 
Although the fear of the HIV vaccine‟s side-effects and attitude of mistrust of the 
researchers subsided among those who participated in the trial (IV), significant others 
played a role in convincing them that the trial was not safe. In this context, the health 
care providers who were not connected to the trial were the most influential. One 
participant narrated what he faced while interacting with one of these providers: 
“When you tell a person that you are involved in something [HIV vaccine 
trial], and he/she comments „he!‟, in your heart you feel: „Does it mean 
that I am lost?‟... I met a specialist, the one they call an orthopaedic 
surgeon. Just by seeing my documents [HIV vaccine trial volunteer], he 
was shocked in such a way that shocked me too … then he called his 
nurse; she also looked at the documents in brief, and then they looked at 
each other. Things like those, we just say, let us go ahead...” (Man 9, 
unmarried, Group 2) - IV 
 
Several participants encountered a similar situation and they were also confused by the 
attitude of mistrust among the non-trial health care providers. After interacting with 
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medical doctors who were poorly informed about the trial, they surrendered and place 
their decision in faith. Therefore, fear and mistrust from different sources emerged as a 
negative response towards participation in the HIV vaccine trial. 
 
Positive enablers: Prevailing benefits & commitment of participating in an HIV 
vaccine trial (I, II, III and IV) 
Participation in the HIV vaccine trial is seen as a personal decision; a belief that 
Tanzania should become a partner in the development of HIV vaccine and a high level 
of knowledge about HIV and AIDS (I). Additionally, participants stated that they 
would volunteer for an HIV vaccine trial because of the services that they would be 
able to access as a result of the trial interventions (II). They believed that a complete 
medical check-up would be a great opportunity to receive free medical services for the 
diseases that may be discovered:  
“Surely, I will be motivated as I think the big issue is to be checked. It‟s 
useful for me since if I am found with problems, I will be attended by 
experts. I will be thankful since I will be given immunity [treatment].” 
(High ranking policeman, group 5) – II 
 
Although some of the eligible participants declined to enrol in the HIV vaccine trial, 
they still saw a benefit in having a good relationship with the trial team (III). One 
participant said:  
“You know what I am ashamed of is to meet such incredible people at the 
clinic; stating that I don‟t want to proceed with the trial! I remember 
doctors, nurses, and counsellors; the way they handled me so friendly 
with a cup of tea with milk ….” No, but my heart doesn‟t encourage me 
to continue [proceed with the trial]…” (Informant 7, woman) – III 
 
On the other hand, the participants who enrolled and stayed on until the end of the trial 
felt confident because of regular contacts with the trial team (IV). They also believed 
that they knew more facts about HIV and vaccine because they had attended the 
workshops. They benefited from HIV testing and general medical check-ups during the 
trial. This practice promoted confidence over their health status and they also gained 
courage and hope through these medical investigations: 
“Everything you [I] checked, you were [I was] told by the doctor, that 
you were [I was] okay … when you [I] went out, you [I] got a relief that 
you [I] did not have any problem. You see, because if a person had 
kidney problems, he was given treatment. Therefore, that gave us courage 
and hope...” (Man 6, married, Group 4)-  IV 
In addition, most of the participants agreed that participation in the trial helped them to 
change from risky to safer sexual practices.  
 
Personal commitment in the trial participation was important. Respondents reasoned 
that they would not tell others about their intention to volunteer for an HIV vaccine trial 
because they believed in their personal decision (I). Further, they emphasized that 
personal motivation to volunteer and altruism to save others lives were the reasons that 
would make them volunteer for an HIV vaccine trial (II). Some quotations illustrate 
these:  
“I will personally see myself as a hero.” (Young policeman 2, Group 4) – 
II. 
Another group participant added: 
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“I will be confident and able to say “I was among the participants” [in the 
HIV vaccine trial].” (Young policeman 3, Group 4) – II. 
 
In addition participants believed that if they volunteer and make the vaccine 
development successful, they would have saved millions of people from HIV infection: 
“I think this [taking part in the trial] is part of motivation in my duty 
because if I get vaccinated and make it successful, I will save the civilians 
whom I protect. And to work as a police officer, there must be people to 
protect. No police force without people. I think this is one of the moral 
principles that I should do.” (Low ranking policewoman 10, Group 3) – 
II. 
 
Furthermore, personal decision emerged as a strong argument against the 
discouragement voiced by significant others (IV). Staying in the trial until the end was 
all about personal commitment as explained by the study participants: 
“It [discouragement] is there. Others were pressing me until I decided to 
tell them, „I have decided to sacrifice myself; I have already sacrificed to 
rescue this world. If it is a vaccine, then it will help other people… Jesus 
died on the cross to save others. So, I sacrifice too.” (Man 7, married, 
Group 4) – IV. 
Through body gestures, other members of the group indicated that this was an 
experience to identify with especially when they interacted with their families. They 
felt that their work involved protecting people and their properties, but through 
participation in the trial, they would also promote the good health of the community.  
They insisted: 
“You have power and not afraid. You sacrifice yourself when you fight 
for your country ...” (Woman 6, unmarried, Group 3) – IV  
To a large extent, participants stated that they managed to ignore negative comments 
from others as narrated in the earlier section because of the level of confidence they had 
in the trial from the start. Thus, personal decision remains a positive „foundation‟ of 
participation in the HIV vaccine trial. Additionally, most of the participants 
demonstrated that the education and other services in the trial were the reason that 
enabled them to stay on in the trial.  
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4 DISCUSSION 
4.1 MAIN FINDINGS 
In this thesis, the discussion loosely draws from all the domains of the PEN-3 model 
and the interwoven findings are discussed together to strengthen the meaning and 
understanding of these issues.  
 
The recognition of significant others (sexual partners, friends, family members, 
relatives or parents) as reliable people to share the information about the trial with (I) 
implies that people in this setting have strong social ties in the sense of helping or 
depending on each other in times of doubt. However, the significant others‟ reaction 
emerges as a major deterrent to volunteering for the HIV vaccine trial (II, III). Similar 
to other studies, it appears that significant others (friends, sexual partners and family) 
may play a significant role in influencing participation in HIV vaccine trials [13, 28, 42, 
110]. In the current study, fear of breaking the dependence chain from young men to 
aging parents signifies the cultural aspect of insurance, which young people are 
expected to offer to the older generation. This also indicates the degree (in cultural 
identity) to which family networks can empower different persons within the family 
and their responsibilities [87]. The fact that some women retract their decision to enrol 
in HIV vaccine trials also implies that gender is becoming very central in the decision 
whether or not to take part. In addition, the continuous struggle to convince significant 
others about trial safety shows the importance of existential nurturers in the form of 
negotiation through information-sharing in social networks to minimize discouraging 
influences. Airhihenbuwa et al refer to existential nurturers as the influence of 
significant others and community contexts in making health decisions and choices 
within certain traditional values and practices [88]. In HIV vaccine trial participation, 
participants are obliged to make decisions in collaboration with significant others to 
maintain the traditional values and practices of consulting each other. However, in 
several of the studies (II, III, IV), the reactions of significant others may be strongly 
intertwined with their attitudes to HIV stigma in the community leading them to be 
negative to the HIV vaccine trial as well. 
 
Moreover, understanding the sexual behaviour of potential or actual participants in an 
HIV vaccine trial in culturally sensitive interventions is important. People value sexual 
matters according to their cultural preference, and some of these preferences may not 
support HIV prevention interventions. The fact that potential trial participants preferred 
to have multiple sexual partners without using a condom, reproduction continuity and 
sexual pleasure implies that trial implementers need to recognize these cultural issues. 
The issues of becoming pregnant and fathering a child are existential perceptions that 
bring attention to cultural identity of fatherhood or motherhood in an African context. 
In Uganda, postponing pregnancy had a major impact on the willingness of women to 
participate in HIV vaccine trials [34]. Thus, fertility concerns and sexual practices may 
be a major concern in an African context. In Maasai community in Tanzania, risky 
sexual behaviour has been used to solve fertility problems for a long time [111], 
suggesting that sexual behaviour is inextricably linked to fertility issues. These are 
existential perceptions which Airhihenbuwa et al refer to as knowledge, attitudes and/ 
or beliefs that influence decisions about HIV/AIDS prevention in a manner that could 
be described as unique to that culture [88]. The authors further explain that such 
perceptions are often not positive or negative but they reflect characteristics and 
qualities that help to explain certain values of people [88].The risky sexual behaviour of 
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having multiple sexual partners may, however, interfere with the use of a partially 
effective vaccine and may even increase with the notion that the vaccine may be 100-
percent protective. Also, understanding stigma in the broader picture of HIV/AIDS in 
an African context may be important in predicting the uptake of the HIV vaccine if it 
were made available.  
 
Fear of an experimental HIV vaccine emerged as a major concern among the study 
participants. This fear was increased by the unknown effect of the vaccine. As shown in 
other studies, participants fear vaccine-induced HIV infection [5, 28]; negative side-
effects of the vaccine [6, 23, 39]; and negative comments from others [110]. 
Discouragement from colleagues and friends suggests there is inadequate or poor 
knowledge about the safety of the trial within the community. The neighbourhood tends 
to influence decisions for its collectives [87].  In the present studies, the highlighted 
fear of the effect of vaccine on reproduction is also noted in other settings [28].  The 
fear of the vaccine‟s adverse effect on reproduction continuity implies that fertility is 
highly valued in Tanzania [112] and in an African context in general [113]. On the 
other hand, the fear of vaccine side-effects is exacerbated by mistrust of the researchers 
conducting trials. In previous studies, government or scientists conducting the trial were 
not trusted [25, 28, 114-115]. This scenario adds challenges to scientific investigations 
and can seriously interfere with future trials in this context, even for other vaccines. 
Airhihenbuwa et al refer to negative perception as knowledge, attitude and/or beliefs 
that negatively influence decisions about HIV/AIDS prevention [88]. 
 
Access to a free and complete medical check-up by participating in an HIV vaccine 
trial is perceived as an incentive (II), implying that people value free health services in 
this context. Although the desire to have a complete medical check-up in the trial was 
in the beginning tempered by a fear of discovering that one was suffering from 
unknown diseases (II), it was eventually seen as a reward in to the form of free access 
to medical services (IV). In Gambia, parents were ready to let their children participate 
in the trial to get free medical treatment [116]. Other studies show that getting free 
counselling and HIV testing are the perceived benefits of participating in HIV vaccine 
clinical trials [31].  Education about the vaccine is also valued as an incentive and 
benefit for people to participate in the trial [16]. Airhihenbuwa refers to institutional 
support such as medical drugs to clients as enablers [88]. 
 
The discovery of one‟s HIV status as a consequence of the routine testing in the trial 
aroused fear (II), but this fear was removed as a result of the trial interventions (IV). 
This change implies that trial interventions may promote understanding of and 
confidence in knowing one‟s own HIV status. The approaches to HIV prevention in 
Tanzania suggest that knowledge of one‟s HIV status can empower individuals to take 
precautionary measures to protect themselves against either acquiring or transmitting 
the disease [68]. In the present study (IV), the experienced change from risky to safer 
sexual behaviour is fuelled by regular monitoring of HIV status and counselling. 
Decrease in risky behaviour during participation in HIV vaccine trials has also been 
noted in previous studies [40, 117-118].     
 
The most prevailing positive response to participation in the current trial is the self-
respect and empowerment expressed by the volunteers. The ability to stand by their 
independent decisions with the notion of doing good for others (altruism) is crucial. 
This altruistic belief is universally documented as a predictor of participation in HIV 
vaccine trials [5, 13, 16, 18, 25, 38, 47, 119-120]. Moreover, the fact that trial 
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participants completed scheduled study visits implies that information or the 
counselling about the trial safety boosted their confidence and trust in the trial. In South 
Africa, the lack of information about vaccines was one of the reason for not deciding to 
volunteer in HIV vaccine trials [14]. The increasing demand for basic HIV vaccine trial 
education [12, 15, 17, 21] implies that people‟s understanding of the trial has an 
important bearing on their decision whether to participate in HIV vaccine trials or not. 
Thus, perhaps knowledge acquisition may motivate those who perceive the trial as an 
important step in helping researchers to find effective HIV vaccines [20]. Moreover, the 
ability to defend personal decisions was enhanced by coping strategies which human 
beings apply when they interact with the social climate [121]. As people deal with the 
notion of advantages and disadvantages during programme interventions [87-88], the 
decision is often in favour of one‟s cultural identity. Airhihenbuwa et al refer to 
positive perception as knowledge, attitudes and/or beliefs that positively influence 
decisions about HIV/AIDS prevention [88]. 
 
4.2 METHODOLOGICAL REFLECTIONS 
Validity (Study I) 
Internal and external validity  
Study I is a quantitative study including a convenience sample of 329, since our 
resources and the setting did not allow us to collect a random sample. The design is not 
optimal since a non-random sample always generates selection bias and decreases 
(external) validity. Also, the study participants were self-selected after a health-related 
workshop. Possibly, non-participants may have affected the reported results because we 
have no knowledge of their characteristics. That means that there is a risk of the sample 
not representing the intended study population, but only a portion of this, sharing 
special characteristics associated with study participation. Hence, inference from this 
study to the general population or to the police force in Dar es Salaam is not possible. 
We have thus aimed to interpret and present the results in a way that makes it clear that 
our results only concern the actual group from which data were collected.  
 
The previous success of conducting research within the police force [75] showed that 
HIV studies could ethically be conducted in such a hierarchical organization. In the 
present studies, the privilege of conducting HIV research among police officers in Dar 
es Salaam, Tanzania, is that most of them have had four years of secondary education; 
they come from an established organization and are easy to access. However, drawing a 
random sample was not possible because of emergency duties. Despite the fact that 
appointments were made, sometimes data collection had to be postponed for a month 
and so on to accommodate emergences (eg. fire or road accidents, theft incidents or 
robbery). Thus, most of the data were collected on a convenience basis. Access to the 
participants was therefore challenging at times, but the participants engaged in the 
study immediately after establishment of the consent process.  
 
In the study, we used interviewer-administered questionnaires. There is in this case 
always a risk of individuals answering in accordance with social desirability (answer 
according to what they feel the researcher may want to hear). For example, revealing 
the number of lifetime sexual partners in a face-to-face interview was difficult for 
women. The nurse counsellors, including myself, noted the hesitation among a few 
respondents in disclosing the number of sexual partners. Hence, there is a risk that 
high-risk sexual behaviour is underestimated, especially among women.  
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Reliability 
We used a questionnaire specifically designed to meet our study requirement. For 
example, we included open-ended questions to justify some of the close-ended 
questions and as an intervention tool where participants could be counselled whenever 
the need arose. The quality of the questionnaire [structured interviews] was reviewed 
and checked for its „mechanical‟ structure; i.e. some questions were ruled out if they 
were unclear or misleading [101]. We pre-tested our interview-administered 
questionnaire and it was established that each time it was administered, it was 
understood the way we expected. Thus, the results can be reproduced using a similar 
tool and under similar methodology (reliability). Reliability is the consistency of the 
measurement or the degree to which an instrument measures the same way each time it 
is used under the same conditions and with the same subjects [122] . We could have 
used an existing standardized questionnaire on knowledge, attitudes about HIV and 
AIDS and sexual practices, but we opted for the designed one to meet our study 
requirement as stated above. 
 
Trustworthiness (II - IV) 
The studies in this thesis were designed for the research questions, and the purpose of 
the studies was to produce knowledge beneficial to humans while minimizing harmful 
effects [123]. In this thesis, participants were appropriately and carefully selected 
according to the purpose of each study. In order to assess trustworthiness of the studies, 
I have used strategies suggested in the literature, namely triangulation, member 
checking, peer debriefing, dependability and reflexivity [124].  
 
Triangulation 
We achieved triangulation of data in this thesis by combining quantitative and 
qualitative methods. Whereas quantitative research focuses on drawing inferences from 
particular observations, qualitative research is usually inductive and provides rich and 
contextual understanding of some aspects of human experience [125]. For example, the 
issues of significant others‟ influence and fear of negative side-effects of the vaccine in 
the trial were first pointed out in the quantitative study (I), and these issues were 
enriched in their actual meaning through the subsequent qualitative studies II-IV. 
Regarding a qualitative approach, focus group discussions and face-to-face interviews 
were employed, and it appeared that data from face-to-face interview in Study III 
complemented that of FGDs in Study II.  
 
Moreover, in this thesis, triangulation of researchers refers to the collaboration of 
different disciplines to design the studies: a sociologist (JM); medical doctors and 
global health experts (AK and AT); qualitative expert with PhD (TWK); and medical 
specialists with expertise in epidemiology and clinical trials (MB, ES). Although I 
(EAMT) was responsible for validating the information in the audio-tapes and 
transcripts, the correctness of the translation from Kiswahili to English, and drafting the 
manuscripts, the tasks of data collection and analysis were performed in collaboration 
with other researchers. For example, moderation of FGDs and the analysis was carried 
out by two researchers to make the interpretations sound. The findings were checked by 
all researchers involved in the project. Thus, collaborative work added quality control 
throughout the stages of knowledge production.  
 
Peer debriefing 
During data collection and analysis, we debriefed the research team and our 
collaborators from the police force by sharing what was emerging from the study. The 
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feedback brought more insight into the analysis and improvement in conduct of the 
subsequent studies. Peer debriefing refers to the presentation of preliminary findings to 
colleagues to help the researcher to evaluate his or her own role in the research process 
[126]. 
 
Member checking 
Member checking refers to a process of confirming findings with the participants to 
ensure that what was understood was credible [126]. The findings from Studies II and 
IV were presented to the study participants and their peers to gain their feedback. Most 
participants reacted positively to the findings and confirmed that they tallied with their 
own experiences and feelings, especially regarding discouragement from significant 
others on the HIV vaccine trial participation. 
 
Dependability  
We enhanced reliability in our qualitative data by employing a good-quality audio-
recorder and transcribing the audio-tapes. The transcripts were verified by the author 
(EAMT) to ensure consistency of the transcribed content. 
 
Reflexivity 
Reflexivity is critical reflection on what has been thought and done in a qualitative 
research project and a conscious attempt by researchers to acknowledge their own 
involvement in the study – a form of self-reference and self-examination in relation to 
the research that is being carried out [99]. In a qualitative inquiry, the researcher gets 
involved in the process of data collection in the field, using his/her interview skills and 
empathetic ability to deal with different situations. As „an instrument‟ in the qualitative 
studies, the researcher calls attention to biases. However, these biases become 
problematic only if the researcher is aware of them [127]. For example, listening to the 
participants‟ arguments against the HIV vaccine trial after HIV vaccine trial workshops 
was sometimes annoying. Perhaps, I thought the trial team was not clear in the way 
they delivered the message or the participants did not get the message correctly. In 
order to gain knowledge and perceptions from the participants, „the knowers‟, it was 
important to be non-judgmental. Thus, being aware of my role as a researcher was 
important.  
 
Multiple roles: (trial team member, researcher, PhD candidate, social scientist, 
lecturer, nurse, civilian, etc.) 
My involvement in the sensitization sessions and recruitment workshops influenced my 
position as a researcher exploring social issues relating to participation in HIV vaccine 
trials among police officers. During data collection, study participants often referred to 
me as the representative from the trial team.  Although I was carrying the umbrella of 
„social scientist‟ in the HIV vaccine trial, the participants often viewed me from 
different angles: “a knowledgeable medical specialist and HIV/AIDS educationist”, 
“HIV/AIDS educator”, “researcher”, “representative from the HIV vaccine trial team” 
and most often they referred to me as „daktari‟ [doctor]. From all these perspectives, I 
feared that the participants would not be transparent about their concerns relating to the 
HIV vaccine trial. I was also afraid that they may refuse to discuss anything negative in 
relation to the trial implementers. However, once they engaged in the consent process, 
they became focused on the research questions and positively reacted to me as a 
researcher. They were also cooperative. I also tried to separate my other roles from 
research and remained as a researcher throughout the data collection.  
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Staying at the police stations after data collection was both socializing and gave me 
access to additional information and perceptions. At one station, a man said a joke: 
„When are you [researchers] /[nurse counsellors] coming to collect our blood again? I 
will give you my blood, but not take part in your vaccine trial! [The colleagues around 
burst out laughing]. Another one added:  „You now, they [trial team] want to give us 
the virus [vaccine], no way! By the way when are you [research team] coming to bring 
the seminars again?‟ This discourse demonstrates how the participants viewed / 
perceived my role in this context, but it established a good relationship without 
contaminating the field environment. 
 
During data collection, my main supervisor (AK) and I encountered different „power‟ 
situations. Immediately after entering the police stations, we felt subservient to the 
police officers (We perceived the police officers like bosses). On the other hand, when 
the police officers came to the trial site, we felt they saw us like bosses; they looked 
obedient and ready to follow instructions from the health care providers/ trial team. 
These two power situations did not, however, influence the access to the data neither at 
the stations nor at the trial clinic. Perhaps the flexibility of qualitative research 
facilitated trust and therefore the levels of power were completely absorbed once data 
collection got under way. 
 
Characteristics of the police officers 
The characteristics of the police officers as an elite group can be seen in some of the 
quotes in this study. Possible influence of the expectation that police officers should 
save the nation even if this entails taking risks and their own personal views of being 
viewed as heroes by others may have contributed to the style of their responses. 
Perhaps it is their power and authority to protect the safety and welfare of the 
community [128] that may have contributed to their participation in HIV vaccine trial. 
However, we cannot base our judgement on this because participation in the HIV 
vaccine trial was voluntary. All steps to ensure that participation was voluntary were 
taken care of by the trial implementers.  
 
The challenge of translation and analysis  
Data was collected in Kiswahili, the national language and then translated into English. 
The benefit of two researchers (EAMT and TWK) being native Swahili speaker 
enhanced the quality of the translations.  However, the Kiswahili language has several 
words which may have multiple meanings unless one reads the whole sentence or 
paragraph. Thus, going back and forth was part of the quality check in the translations. 
Sometimes, both Kiswahili and English quotes were included in the draft manuscript 
for final agreement in translation consistency.  
 
Transferability  
The characteristics of our participants, data collection methods and analysis are 
described in detail. Since all the studies were carried out among police officers, the 
findings can only be applied in similar settings to enhance understanding of the 
phenomenon [124]. However, police officers in this context may share some 
similarities such as relationships with significant others in the community, but may 
differ in terms of training, roles and responsibilities. Therefore, our findings can be 
transferred to a setting similar to our study setting and population. Transferability refers 
to the extent to which the findings of a qualitative research study can only be 
transferred to other contexts or settings or groups. In this perspective, transferability 
should rely on the one transferring and wanting to generalize the findings.  
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5 CONCLUSIONS 
Based on the findings described in the articles and summarized in this thesis, the main 
conclusions are: 
 Positive outcomes of the trial and expectations of getting protection from the 
trial were important for participants to volunteer in the HIV vaccine trial.  
 Participation in an HIV vaccine trial was in this context perceived as both a 
family and a personal decision.  
 Individuals‟ decisions and trial-related interventions such as counselling, free 
(insured) medical services were important incentives in the retention of the 
volunteers in the Phase I/II HIV vaccine (HIVIS03) trial.  
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6 RECOMMENDATIONS  
6.1 PRACTICE 
This study produces useful information for trial implementers regarding tentative ways 
of engaging the community in the scientific efforts of searching for an effective 
preventive HIV vaccine through clinical trials: 
 
In line with the PEN-3 model, modification of recruitment strategies such as involving 
those who form close social relationships with the potential trial participants from the 
start of the trial is crucial. For example, in the ongoing HIV vaccine trials in Dar es 
Salaam, Tanzania, the presence of significant others (Extended family) is being 
acknowledged by trial implementers by actively involving them in the trial recruitment 
process, to share their concerns with the trial experts. Extra attention is given to 
potential volunteers to make sure that they understand all aspects of the trial and make 
independent decision on whether to participate in the trial or not. Thus, the potential 
volunteers (Person) are encouraged to make individual decisions after understanding 
the importance of participation in the trial. At the same time, both significant others and 
potential volunteers are discouraged from relying on rumours and misconceptions 
about HIV vaccine trial safety from the surrounding communities (Neighbourhood). 
They are also encouraged to spread positive and correct messages in their 
neighbourhood.  
 
Moreover, the findings call for: 
 Use of examples from this study to amend the existing AIDS educational 
materials or tools by incorporating positive HIV vaccine trials‟ information; 
 Producing simple statements on the concepts that are most important to 
communicate to the community, especially those which are commonly 
misunderstood in the study, for example, the safety of the HIV vaccine trials or 
the fact that a volunteer can not be infected by HIV infection from the candidate 
vaccine; 
 Developing materials for wider dissemination and such materials should be 
pretested among various groups (youths/students, community 
leaders/community groups) to incorporate their feedback in the final version; 
 Involving stakeholders at higher levels from planning to the conduct of clinical 
trials which may be useful in maximizing trust on the clinical trials, for 
example: 
 Members of the Parliament, policymakers and the MOHSW are the most 
influential bodies. As stated in the Aids Tool kit, they have important roles 
at the local, national and global levels of AIDS vaccine work, and are 
often involved in high-level decisions.  Good examples are seen in 
Thailand, South Africa, Kenya, Uganda, India, Rwanda and Brazil where 
AIDS vaccine is on the agenda [9]. 
 
 Involving media and journalists is important because they serve as an 
important information source for the community and to a larger extent can 
be influential in shaping public opinion at all levels. However, caution 
should be taken to make sure that they have accurate and up-to-date 
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information about the respective clinical trial(s) because they may 
unintentionally spread misinformation that may fuel an attitude of mistrust 
of the vaccine trials and the involved scientists. 
 
 The study findings direct our attention to the health care providers 
(doctors, nurses and other health workers) who are not directly involved in 
HIV vaccine trial research. These people should be correctly informed 
about the clinical trials because community members often consult them 
for health-related advice. It is therefore important to disseminate the HIV 
vaccine trial facts to all health care providers in setting where the trial is 
being conducted. In a long term, introducing the clinical trials education in 
medical curriculum may be useful to build up trust in clinical trials among 
all medical professionals. 
 
 Also, religious leaders need to be involved in information dissemination 
because they have influential power in shaping the opinions of their 
followers including making important decisions such as participation in 
HIV vaccine trials. 
 
 Liaison with the Community Advisory Boards in the respective settings is 
important because they can support recruitment of volunteers by 
disseminating correct information. and providing feedback on trial 
protocols (informed consent forms and processes) [9]. 
 
In summary, the Good Participatory Practice guidelines for biomedical HIV prevention 
trials provide a list of stakeholders which include trial participants; families of trial 
participants; community members residing in the neighbourhood; the research 
catchment area; people living with AIDS or affected by HIV; advocates and activists; 
non-governmental organizations; community-based organizations; religious leaders; 
opinion leaders; media; government bodies; national and local health care authorities; 
service providers; trial funders; trial sponsors and trial implementers [129]. 
 
6.2 RESEARCH  
Building on these findings, further studies should be planned to examine their 
significance for policy formulation when conducting HIV vaccine trials with different 
groups in similar settings. For example, there is already an ongoing study among 
youths in Dar es Salaam, Tanzania to further explore the issues presented in this thesis. 
For example, the extent of influence of significant others on youths in participation in 
HIV vaccine trials is being quantitatively determined.  
 
Moreover, longitudinal studies to monitor possible post-trial behaviour change are 
important. In relation to this, a study on prolonged follow-up of HIVIS03 volunteers is 
going on, and examination of risk sexual practices and other social issues are integrated 
in this follow-up project. 
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9 APPENDICES 
9.1 APPENDIX I 
Stages of conducting clinical trials in human beings and the safety aspects 
Stages 
Phase I: This is a clinical trial with a small no. of ~60 healthy volunteers, at low risk, 
aiming at testing for vaccine‟s safety  
Phase II: This stage involves 50-500 healthy individuals to test for immunogenicity in 
humans 
Phase III: This is a larger controlled clinical trial with thousands of volunteers to 
determine efficacy of the vaccine [9]. 
 
Safety about the clinical trials  
The candidate AIDS vaccines being developed and tested in humans cannot cause HIV 
infection for the following reasons: 
 Vaccines being tested in clinical trials do NOT contain the entire virus. 
 The vaccines contain either a protein that resembles the outer coat or other part 
of HIV, or they contain manufactured copies of small segments of genetic 
material resembling that of HIV; no single protein or gene could cause HIV 
infection. 
 The genes contained in the vaccines are copies of HIV genes, meaning 
scientists have produced them in laboratories, so the final genes put into the 
vaccines have never been part of an actual virus [9]. 
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9.2 APPENDIX II 
a) Application of Cultural Empowerment components in the study results  
Study’s objective Positive  Existential  Negative  
I 
Factors associated 
with willingness to 
volunteer in an 
HIV vaccine trial  
“Participation in a trial 
is a personal decision” 
[narrated reason]” 
“Tanzania becoming a 
partner in development 
of HIV vaccine: OR, 
4.28”  
 “High knowledge 
about HIV and AIDS: 
OR, 1.92”  
 “Intention to tell others 
(friends, family members, 
relatives or parents) about 
decision to participate in the 
trial”  
“Having extra sexual partner” 
“Not using condom” 
 
 
“Fear of vaccine side-
effects” 
“Lack of trust in vaccine 
trials” 
„Risk behaviour” 
 
II 
Reasoning around 
the decision to 
volunteer for the 
HIV vaccine trial 
“Individual 
motivations (personal 
pride and confidence in 
a decision to 
participate in a trial)” 
“Altruism (obligation 
to protect others, and 
self-sacrifice to save 
lives of others)” 
“Reproduction and pregnancy 
norms (desire to become 
pregnant)” 
“Responsibility for others 
(young ones provide 
insurance to the old 
generation)”  
“Influence of the significant 
others in decision-making”  
“Sex is a source of pleasure” 
“Stigma” 
“Risk for HIV infection, 
myths about the vaccine‟s 
side-effects” 
“Fear of routine tests and 
follow-ups in the trial” 
“Mistrust of researchers in 
the trial” 
III 
Reasons for 
declining to enrol 
in the HIV vaccine 
trial after  
randomization 
“Personal intentions to 
volunteer for an HIV 
vaccine trial”  
 
 
 
“Consultations within the 
social networks in times of 
doubt” 
“Importance of fathering a 
child” 
“Concerns about condom use 
in consensual relationships” 
“Unknown side-effects of 
the vaccine in the body” 
“Mistrust of the researchers‟ 
intentions” 
“Discouragements from 
significant others” 
IV 
Experiences of 
volunteers who 
participated in 
HIV vaccine trial  
“Pride of fulfilment 
and self-respect by 
participating in an HIV 
vaccine trial” 
“Convincing the family about 
the trial safety” 
“Pregnancy concerns” 
“Stigma” 
“Mistrust from health care 
providers outside the trial” 
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b) Application of relationships and expectations components in the study results  
Study’s objective Perception Enablers Nurturer  
I 
Factors associated 
with willingness to 
volunteer in an 
HIV vaccine trial  
“Positive attitude towards 
using an effective vaccine 
if available: Odds ratio 
(OR), 36.48  
 “Possible protection 
from HIV infection” 
“High knowledge about 
HIV and AIDS”  
 
 
“Intention to tell others 
(friends, family members, 
relatives or parents) about 
decision to participate in the 
trial”  
 
II 
Reasoning around 
the decision to 
volunteer in the 
HIV vaccine trial 
“Altruism (obligation to 
protect others, and self-
sacrifice to save lives of 
others)” 
“Others will perceive the 
trial participants 
negatively (stigma)” 
 
“Medical check-ups and 
free health services” 
“Researchers‟ assurance 
about the trial” 
 
“Concerns for significant 
others on pregnancy norms” 
 
III 
Reasons for 
declining to enrol 
in the HIV vaccine 
trial after  
randomization 
“Personal decision” 
“Vaccine trial may 
interfere with sexual life” 
 
Good relationship with 
the trial team 
Significant others‟ 
discouragement affecting 
individuals‟ decision to enrol 
in the trial 
IV 
Experiences of 
volunteers who 
participated in 
HIV vaccine trial 
“Personal intention to 
volunteer in an HIV 
vaccine trial”  
“Belief in ability to 
change from risky to 
positive behaviour” 
 
 “Follow-ups: Routine 
check-ups, education and 
counselling in the trial” 
“Condom use” 
“Convincing the family about 
the trial safety” 
 
 
     
 
